There was no differentiation in the effects of node knock-out in KRAS WT or mutant cell lines, indicating the need for treating individual mutants as their own entity, rather than “KRAS-mutant cancer.” Instead, tissue of origin seemed to more closely associate with node sensitivity. Here, KRAS is linked to cancer.